Oxaliplatin and/or gemcitabine vs. FOLFIRINOX in first-line Advanced pancreatic adenocarcinoma: Real-world efficacy and safety data of moroccan patients
Background: While fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) offers a survival advantage in advanced pancreatic adenocarcinoma (PAC) compared to gemcitabine, gemcitabine-oxaliplatin, and gemcitabine-nab-paclitaxel, the outcome of these regimens in African countries is still i...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2025-01-01
|
| Col·lecció: | Cancer Treatment and Research Communications |
| Matèries: | |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S2468294225001728 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|